- Home
- / CanSino Biologics
CanSino Biologics
Revenue
¥1.1 B
FY, 2025
CanSino Biologics Summary
Company Summary
- Overview
- CanSino Biologics (康希诺生物股份公司) is a biopharmaceutical company that provides solutions for the prevention and treatment of infectious diseases. It researches, develops, and manufactures vaccine products for human use.
- Type
- Public
- Status
- Active
- Founded
- 2009
- HQ
- Tianjin, CN | view all locations
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Shoubai Chao, Chief Operating Officer, Executive Director
Tao Zhu, Chief Scientific Officer
Dongxu Qiu, Co-Founder
LocationsView all
1 location detected
Tianjin, Tianjin HQ
China
Biomedical Park, 185 South Avenue
CanSino Biologics Financials
Summary Financials
- Revenue (FY, 2025)
- ¥1.1B
- Gross profit (FY, 2025)
- ¥1.1B
- Net income (FY, 2025)
- ¥27.9M
- Cash (FY, 2025)
- ¥1.2B
- EBIT (FY, 2025)
- ¥17.5M